Currently, there are 83.98M common shares owned by the public and among those 75.96M shares have been available to trade.
However, the script later moved the day high at 22.00, down -8.03%. The company’s stock has a 5-day price change of -20.84% and -3.41% over the past three months. INMD shares are trading -5.71% year to date (YTD), with the 12-month market performance down to -47.17% lower. It has a 12-month low price of $18.57 and touched a high of $48.25 over the same period. INMD has an average intraday trading volume of 1.67 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -12.58%, -7.88%, and -30.83% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Inmode Ltd (NASDAQ: INMD) shares accounts for 66.80% of the company’s 83.98M shares outstanding.
It has a market capitalization of $1.77B and a beta (3y monthly) value of 2.21. The stock’s trailing 12-month PE ratio is 9.10, while the earnings-per-share (ttm) stands at $2.31. The company has a PEG of 2.93 and a Quick Ratio of 12.29 with the debt-to-equity ratio at 0.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.59% over the week and 4.30% over the month.
Analysts forecast that Inmode Ltd (INMD) will achieve an EPS of $Mind Medicine (MindMed) Inc. for the current quarter, $5.07 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Innodata Inc. while analysts give the company a high EPS estimate of $INmune Bio Inc.. Comparatively, EPS for the current quarter was $CONMED Corporation a year ago. Earnings per share for the fiscal year are expected to decrease by -0.76%, and 5.93% over the next financial year. EPS should shrink at an annualized rate of 3.10% over the next five years, compared to 47.29% over the past 5-year period.
Looking at the support for the INMD, a number of firms have released research notes about the stock. UBS stated their Neutral rating for the stock in a research note on November 03, 2023, with the firm’s price target at $52-$24. Canaccord Genuity coverage for the Inmode Ltd (INMD) stock in a research note released on October 13, 2023 offered a Hold rating with a price target of $22. Barclays on their part issued Overweight rating on December 21, 2022.
